440 related articles for article (PubMed ID: 35565395)
1. Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.
Zhou Y; Li M; Zhou K; Brown J; Tsao T; Cen X; Husman T; Bajpai A; Dunn ZS; Yang L
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565395
[TBL] [Abstract][Full Text] [Related]
2. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
[TBL] [Abstract][Full Text] [Related]
3. [Basic Research and Clinical Development of Regenerative Immunotherapy Using iPS Cells].
Kanie K; Kaneko S
Gan To Kagaku Ryoho; 2023 May; 50(5):571-576. PubMed ID: 37218314
[TBL] [Abstract][Full Text] [Related]
4. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
Zhu H; Kaufman DS
Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
[TBL] [Abstract][Full Text] [Related]
5. IPSC-derived CAR-NK cells for cancer immunotherapy.
Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
[TBL] [Abstract][Full Text] [Related]
6. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract][Full Text] [Related]
7. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.
Tsiverioti CA; Gottschlich A; Theurich S; Anders HJ; Kroiss M; Kobold S; Trefny M
Biol Chem; 2024 May; ():. PubMed ID: 38766710
[TBL] [Abstract][Full Text] [Related]
8. Advancing cell-based cancer immunotherapy through stem cell engineering.
Li YR; Dunn ZS; Yu Y; Li M; Wang P; Yang L
Cell Stem Cell; 2023 May; 30(5):592-610. PubMed ID: 36948187
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
Mehra V; Chhetri JB; Ali S; Roddie C
Biology (Basel); 2023 Nov; 12(11):. PubMed ID: 37998018
[TBL] [Abstract][Full Text] [Related]
10. Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy.
Aoki T; Motohashi S; Koseki H
Inflamm Regen; 2023 May; 43(1):27. PubMed ID: 37170375
[TBL] [Abstract][Full Text] [Related]
11. Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies.
Li YR; Dunn ZS; Zhou Y; Lee D; Yang L
Cells; 2021 Dec; 10(12):. PubMed ID: 34944002
[TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
[TBL] [Abstract][Full Text] [Related]
13. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
14. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
16. Next Generation Natural Killer Cells for Cancer Immunotherapy.
Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
Front Immunol; 2022; 13():886429. PubMed ID: 35720306
[TBL] [Abstract][Full Text] [Related]
17. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
18. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy.
Xue D; Lu S; Zhang H; Zhang L; Dai Z; Kaufman DS; Zhang J
Trends Biotechnol; 2023 Jul; 41(7):907-922. PubMed ID: 36858941
[TBL] [Abstract][Full Text] [Related]
19. Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.
Netsrithong R; Wattanapanitch M
Front Immunol; 2021; 12():759558. PubMed ID: 34650571
[TBL] [Abstract][Full Text] [Related]
20. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
